Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics is a clinical-stage biotechnology company with a strong focus on developing innovative drug candidates utilizing its POZ Platform delivery technology. Their main product candidate, SER-252, has shown promising results in treating Parkinson's disease and has the potential to become a blockbuster drug in the future. While facing common industry risks, the company has secured FDA approval for a faster regulatory pathway and continues to conduct trials for its drug candidates, positioning itself for potential success in the market.

Bears say

Serina Therapeutics is a clinical-stage biotechnology company with a negative outlook due to concerns about its technology platform, regulatory risks, and commercial potential. The company's POZ platform, which delivers drugs using polymer technology, may have potential limitations compared to other existing polymer technologies, and the recent clinical hold raises questions about the FDA's oversight. Furthermore, the market for advanced Parkinson's disease treatments is already crowded and the company may face challenges in obtaining pricing and reimbursement for its product candidate, SER-252. Additionally, while Serina has a deeper pipeline, its reliance on partnerships introduces uncertainty and decreases potential revenue.

SER has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 1 analysts, SER has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.